Chimeric antigen receptor T-cell therapy (CART) has extended survival of patients with
relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability of …

Chimeric antigen receptor T cell (CAR-T) therapy is approved for treatment of
relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). Here we evaluate whether …

Diffuse large B cell lymphoma (DLBCL) is the most prevalent subtype of non-Hodgkin
lymphoma. Although outcomes to frontline therapy are encouraging, patients who are …

ABSTRACT CD19-targeted chimeric antigen receptor (CAR) T cells have shown excellent
activity against relapsed and refractory (R/R) diffuse large B cell lymphoma (DLBCL). CAR T …

Chimeric antigen receptor (CAR) T-cell therapy has emerged as an option for
relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures …

Autologous hematopoietic stem cell transplantation (ASCT) and chimeric antigen receptor T‐
cell therapy (CART) are salvage therapies that are utilised for treatment of relapsed or …

Introduction Chimeric antigen receptor T-cell (CAR T) therapy offers a potentially curative
option for patients with relapsed and refractory hematologic malignancies, including diffuse …

The prognosis of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma
(DLBCL) is poor. Chimeric antigen receptor (CAR) T-cell therapy has been approved for R/R …

Chimeric antigen receptor-engineered T (CART) cells are a promising new treatment option
for patients with multiply relapsed and refractory (R/R) diffuse large B cell lymphoma …

Chimeric antigen receptor T-cell therapy (CAR-T) is a major advance in managing
aggressive relapsed or refractory B-cell lymphomas; however, relapses are frequent and …